Search Results

American Society of Nuclear Cardiology Releases New 2026 Guidelines for Stress Testing in SPECT and PET Myocardial Perfusion Imaging

The American Society of Nuclear Cardiology (ASNC) has recently developed and released the "2026 ASNC Guidelines for Stress Testing in SPECT and PET Myocardial Perfusion Imaging." The guidelines have been published online in the Journal of Nuclear Cardiology and will replace the 2016 version to reflect changes in the field of nuclear cardiology over the past decade in terms of technology application, examination workflows, and clinical assessment. The new guidelines focus on stress testing in single-photon emission computed tomography (SPECT) and positron emission tomography (PET) myocardial perfusion imaging, updating recommendations on patient preparation, selection of stress testing modalities, safety management, protocols for different imaging modalities, image interpretation, and report writing. The guideline chair and lead...

2026-09-10

South Korea's First Animal Radiopharmaceutical Approved for the Treatment of Feline Hyperthyroidism

The Korea Atomic Energy Research Institute announced on September 10 that Thyrokitty Injection (I-131), a radiopharmaceutical for the treatment of feline hyperthyroidism developed by the research team led by Dr. Lim Jae-cheong, has obtained an animal drug manufacturing license issued by the Animal and Plant Quarantine Agency of South Korea. This is South Korea's first animal radiopharmaceutical to receive final product approval, marking the transition of related technologies that had previously been mainly at the R&D stage into clinical therapeutic application for pets. Feline hyperthyroidism is a relatively common endocrine disease in older cats, mainly characterized by excessive secretion of thyroid hormones. According to reports, approximately 10% of cats aged 10 and above may suffer from this disease. Traditional treatment methods typically require...

2026-09-10

Domestically Developed "Boron Neutron Capture Therapy System" Enters the National Special Review Procedure for Innovative Medical Devices

Recently, the Medical Device Technical Review Center of the National Medical Products Administration issued a public notice on the review results of applications for the Special Review Procedure for Innovative Medical Devices (No. 14 of 2026). The boron neutron capture therapy system independently developed by Huapeng Neutron Technology (Hangzhou) Co., Ltd. has officially entered the National Special Review Procedure for Innovative Medical Devices after the public notice period. Screenshot from the official website of the Medical Device Technical Review Center of the National Medical Products Administration. The Special Review Procedure for Innovative Medical Devices is a review channel established by the National Medical Products Administration to encourage medical device innovation and promote the application of new technologies, effective since December 1, 2018. According to the relevant procedures, drug regulatory authorities and technical institutions will, on the premise of not lowering standards and not reducing procedures,...

2026-09-10

ITM and SpiroChem Announce Strategic Collaboration to Advance Novel Radiopharmaceutical Development

Garching/Munich, Germany and Basel, Switzerland, September 8, 2026 – Radiopharmaceutical biotechnology company ITM Isotope Technologies Munich SE and Swiss collaborative research organization SpiroChem AG today announced a strategic drug discovery partnership focused on a novel radiopharmaceutical candidate within ITM's pipeline. The specific target and financial terms of the collaboration were not disclosed. Under the agreement, the parties will combine their respective capabilities to advance candidate discovery and optimization. SpiroChem will leverage its drug discovery platform, macrocycle library, and screening engine to lead hit identification and optimization, while ITM will provide...

2026-09-09

Penza State University in Russia Develops Training Simulator for X-ray Image Defect Recognition

Researchers at Penza State University in Russia have developed an interactive training simulator for identifying defects in X-ray images, aimed at helping medical students and residents more accurately assess abnormalities in medical images and understand the physical causes behind different image defects. X-ray image quality directly affects the efficiency of pathological change detection and clinical diagnostic judgment. Factors such as equipment condition, exposure parameters, radiation dose, and quantum noise levels can all lead to degraded image quality. Therefore, radiologic technologists and radiologists need not only to identify lesions in images, but also to assess image quality and determine whether defects such as low contrast, noise, blur, and artifacts may affect diagnosis...

2026-09-09

GE HealthCare's StarGuide GX Digital 4D CZT SPECT/CT Receives FDA 510(k) Clearance in the U.S.

GE HealthCare recently announced that its new digital 4D CZT SPECT/CT system, StarGuide GX, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The system had previously obtained CE marking, and this U.S. clearance marks progress in the clinical adoption of its next-generation molecular imaging technology. Designed for theragnostics and precision medicine needs, StarGuide GX is a comprehensive SPECT/CT system. It supports imaging at multiple energy levels, enables general-purpose SPECT imaging, and is tailored for emerging tracer applications, including investigational α-emitters, aiming to provide imaging support for clinicians and researchers exploring new pathways in diagnosis, treatment planning, and therapeutic response monitoring.

2026-09-09

Australia's First ZAP-X Gyroscopic Radiosurgery Platform to Be Installed at St Vincent's Hospital Sydney

ZAP Surgical Systems has announced that GenesisCare will become the first cancer treatment provider in Australia to introduce the ZAP-X Gyroscopic Radiosurgery® platform. The device is expected to be installed this month at GenesisCare's center at St Vincent's Hospital in Sydney, New South Wales, with the first patients anticipated to begin treatment before the end of the year. The deployment of the ZAP-X platform will enhance GenesisCare's neuro-oncology treatment capabilities in Sydney, enabling it to deliver dedicated stereotactic radiosurgery (SRS). Previously, SRS patients were primarily treated using cobalt-60 systems and multi-purpose radiotherapy linear accelerators. The ZAP-X, in contrast, is a dedicated platform designed for non-inv...

2026-09-09

Alpha-9 Oncology Initiates Phase 1 Clinical Trial of GRPR-Targeted Radiotherapy, First Patient Dosed

Alpha-9 Oncology, a U.S. clinical-stage radiopharmaceutical company, recently announced that the first patient has been dosed in its Phase 1 clinical trial evaluating two GRPR-targeted radiopharmaceuticals. The study involves the actinium-225-labeled compound 225Ac-A9-0642 and the lutetium-177-labeled compound 177Lu-A9-0631, primarily enrolling patients with breast cancer and other solid tumors, with data expected to be released by the end of 2027. According to the company, both 225Ac-A9-0642 and 177Lu-A9-0631 target the gastrin-releasing peptide receptor (GRPR). GRPR is considered a solid tumor-associated target with potential clinical value in breast cancer and other solid tumors. 225Ac-A9-0642 is Alpha-9's first actinium-225 GRPR-targeted compound to enter clinical evaluation...

2026-09-09

U.S. Research Team Discovers Strong Ultrafast Optical Response Induced by Ionizing Radiation, Potentially Advancing Medical Imaging and Sensing Technologies

September 3 news, Stanford University and the U.S. Department of Energy's SLAC National Accelerator Laboratory research team used ultrafast electron and laser pulses to observe a strong ultrafast optical response triggered by ionization processes in semiconductor materials. The related research has been published in Nature Photonics. The researchers believe this discovery could provide new insights for radiography and sensing technologies, and also offer experimental evidence for understanding the fundamental behavior of materials under high-energy particle interactions. Radiation detection is a key technology in particle accelerators, scientific instruments, medical imaging, and security screening equipment. Existing detectors typically face a trade-off between signal strength and response speed: processes with stronger signals tend to be slower, while those with faster response may produce weaker signals...

2026-09-08

South Korea's DuChemBio to Build Country's First Radiopharmaceutical CDMO Plant

South Korean radiopharmaceutical therapy company DuChemBio will build the country's first contract development and manufacturing organization (CDMO) plant dedicated to radiopharmaceuticals, in response to growing demand for radiopharmaceuticals used in the diagnosis and treatment of cancer and neurological diseases. DuChemBio is a subsidiary of healthcare distributor Geo-Young Group. The company recently signed an investment agreement with North Jeolla Province and the city of Jeongeup to invest KRW 34.3 billion (approximately USD 25.5 million) in building a new plant in Jeongeup. The company stated that this is the largest investment since Geo-Young acquired DuChemBio. According to the plan, the new facility will integrate radioisotope production...

2026-09-08

Cancer Hospital of the First Hospital of Jilin University Established, Granted Configuration Permit for Heavy Ion Radiotherapy System

Recently, the 7th Bethune Conference on New Advances in Cancer Treatment was held in Changchun, Jilin Province. The conference coincided with the 80th anniversary of Jilin University and the 20th anniversary of the Cancer Center of the First Hospital of Jilin University, aiming to establish a high-level academic exchange platform and promote the continuous improvement of cancer diagnosis and treatment capabilities in the three northeastern provinces. During the conference, the inauguration ceremony of the Cancer Hospital of the First Hospital of Jilin University was also held. According to reports, the newly established Cancer Hospital will, based on the coordinated development of the original Cancer Center, integrate three advantageous disciplines—oncology, hematology, and radiation oncology—further improve the multidisciplinary collaborative diagnosis and treatment model, promote smoother connections in cancer diagnosis and treatment processes, and enhance comprehensive treatment capabilities for difficult cancers. The conference also...

2026-09-08

Japanese Research Uses Tau PET to Reveal Association with Symptom Progression in Progressive Supranuclear Palsy

A research team at the National Institutes for Quantum Science and Technology (QST) in Japan recently announced findings from a study on progressive supranuclear palsy (PSP). Using their self-developed tau PET imaging technology, the researchers conducted follow-up scans on the same group of PSP patients at approximately one-year intervals, confirming for the first time in living brains that the faster tau protein accumulates in the globus pallidus region deep within the brain, the faster patient symptoms progress. The findings were published on September 5, 2026, in the international neurology journal *Movement Disorders*. Characteristic tau protein accumulation regions in PSP Progressive supranuclear palsy is a progressive neurodegenerative disease occurring in middle-aged and older adults, with common manifestations including increased risk of falls, difficulty with movement, eye movement disorders, postural instability, and cognitive dysfunction. There is currently no therapy that can cure or halt disease progression; therefore, establishing biomarkers that can objectively reflect disease changes and treatment efficacy has been a critical issue in drug development. Previous autopsy studies have shown that abnormal tau protein accumulation in the brains of PSP patients is an important pathological feature, particularly concentrated in deep brain regions such as the globus pallidus and midbrain. However, autopsy samples cannot be used for long-term dynamic observation, and how tau protein accumulation changes over time and how it corresponds to symptom progression had previously remained unclear. In recent years, positron emission tomography (PET) has made it possible to observe tau protein in living brains, but existing studies have mainly shown that tau protein increases over time without sufficiently demonstrating a direct association between these changes and symptom worsening. In this study, the research team used the PET radiopharmaceutical 18F-PM-PBB3 developed by QST, namely florzolotau (18F), to perform two PET examinations on 26 PSP patients and 10 healthy controls, conducted at baseline and approximately one year later. The researchers combined 57 brain regions identified by MRI and performed multivariate analysis of PET signal changes to identify PSP-related tau protein accumulation regions and their spread over time. The results showed that at baseline, tau protein in PSP patients was primarily accumulated in subcortical regions such as the globus pallidus and midbrain, consistent with previous reports. Follow-up imaging at one year showed further increases in tau protein accumulation in the globus pallidus, along with marked increases in tau accumulation in the frontoparietal lobes and cerebellar white matter, suggesting that during the course of PSP, tau protein may spread from deep brain regions to the cerebral cortex and cerebellar-related areas. The research team further focused on Richardson's syndrome, the most typical and common subtype of PSP. This subtype typically progresses rapidly, and the 18 patients with this subtype included in this study showed significant increases in PSP rating scale scores within one year. The analysis found that changes in tau protein accumulation in the globus pallidus showed the strongest correlation with the degree of symptom progression; that is, the faster tau protein accumulated in this region, the more pronounced the worsening of patient symptoms. Analyses of individual patients likewise showed that globus pallidus tau protein accumulation can reflect the course of PSP from mild to severe stages. The researchers believe that serial tau PET imaging has the potential to serve as a novel imaging biomarker for assessing PSP disease progression, and also provides a basis for tau-targeted therapeutic strategies: if future therapies can inhibit tau protein accumulation, it may be possible to slow symptom progression. Next steps still require longer-term follow-up in a larger number of patients to validate the relationship between changes in tau protein accumulation and overall symptom progression and treatment response. The imaging assessment method established in this study may not only be used for disease monitoring and clinical trial efficacy evaluation in PSP, but may also be extended to research on other tau protein-related neurodegenerative diseases and dementias, providing new technical support for the diagnosis and therapeutic development of related diseases.

2026-09-07

Russia masters production technology of ultra-pure germanium for gamma detectors

The Giredmet Research Institute, part of Rosatom, recently announced that its researchers have developed technology for producing high-purity germanium (HPGe) for gamma-ray detectors. This breakthrough is expected to replace imported crystals and promote the formation of a complete production cycle for detector equipment within Russia. According to reports, experts at Giredmet have designed and manufactured experimental equipment, and based on this, developed a process for preparing ultra-high-purity germanium single crystals. The purity of the germanium material reaches at least 7N, i.e., 99.99999%, equivalent to only one impurity atom per 10 million atoms of the primary material. The institute stated that the first batch of experimental samples has been obtained, verifying the effectiveness of the adopted deep germanium purification method in achieving the purity level required for detector applications.

2026-09-07

Russian Researchers Propose New Method for Preparing Iron-59 Magnetite Nanoparticles, Potentially Advancing Nuclear Medicine Diagnostics and Therapy

Russian researchers have developed a new method for preparing iron-59-labeled magnetite nanoparticles, which is expected to provide a new material preparation pathway for medical applications such as magnetic resonance imaging, single-photon emission computed tomography, and radionuclide therapy. According to reports, researchers from the Vernadsky Institute of Geochemistry and Analytical Chemistry and the Karpov Institute of Physical Chemistry, both under the Russian Academy of Sciences, have proposed synthesizing iron-59 magnetite nanoparticles using the sol-gel method. The relevant findings have been published in the journal Applied Radiation and Isotopes. The sol-gel method is a chemical approach for preparing nanomaterials, with the core process involving the conversion of a liquid colloidal solution into a gel-like network...

2026-09-07

Atom High-Tech Signs Memorandum of Cooperation with Cambodia's Calmette Hospital and Others to Advance Nuclear Medicine Capacity Building

On September 4, Atom High-Tech, Cambodia's Calmette Hospital, and FFS Company held a trilateral memorandum of cooperation signing ceremony in Beijing. Huo Yingying, Deputy Secretary of the Party Committee of China Isotope & Radiation Corporation (CIRC), attended and delivered a speech, while Zhang Yiming, Secretary of the Party Committee and Chairman of Atom High-Tech, signed on behalf of the company. Established in 1950, Calmette Hospital is one of Cambodia's largest and most technologically advanced public hospitals and serves as a national referral center. It undertakes three core missions: delivering high-quality medical services, training health professionals, and conducting medical research. Currently, the hospital is actively advancing its nuclear medicine capacity by establishing the country's first nuclear medicine department, further improving its oncology diagnosis and treatment and molecular imaging service systems...

2026-09-07